We’re proud to announce the completion of a $17.2 million seed financing round. These funds will support advancing our thymus-based therapies, moving them towards clinical trials for the treatment of immune-mediated diseases caused by abnormalities in #immunetolerance such as cancer, autoimmunity, transplant rejection, and more. Learn more about the news and our commitment to making a meaningful impact in the lives of these patients: https://lnkd.in/dd2mtAzG ? #immunetolerance #thymushealth #thymus #diseaseprevention #celltherapy, #advancedtherapeutics #regenerativemedicine #longevity
Tolerance Bio
生物技术研究
Dedicated to increasing healthspan by restoring and preserving the function of the thymus.
关于我们
Dedicated to increasing healthspan by restoring and preserving the function of the thymus.
- 网站
-
www.tolerancebio.com
Tolerance Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 类型
- 上市公司
- 创立
- 2023
Tolerance Bio员工
-
Francisco Leon
Immunologist, Entrepreneur, CEO Tolerance Bio
-
Christian Blount, MBA, MS, PMP
Senior Director, Program Management at Tolerance Bio
-
Manasi (Mon-see) Sinha Jaiman, MD, MPH
Chief Medical Officer, Aardvark Therapeutics
-
Ruben Sebastian
Life Science Investor | Venture Capital | Corporate Strategy | Biotech company builder
动态
-
We are excited to share that our Founder and CEO, Francisco Leon, will be speaking at the Sino-American Pharmaceutical Professionals Association (SAPA) Annual Meeting. The event’s theme, “Redefining Medicine: Navigating Resilience, Transforming Lives,” aligns with Tolerance Bio’s mission to develop transformative medicines that restore immune balance and address the root cause of autoimmune diseases. Francisco will be sharing insights from his extensive experience in drug repositioning, including examples from his work at Celimmune, Provention Bio, and our current innovations at Tolerance Bio. For more details, visit the SAPA Annual Meeting website: https://lnkd.in/eJv-JwN6 #SAPA2024 #SAPA #SAPAAC ?#biotech #drugdevelopment #healthcareinnovation
-
-
This week, we are proud to have our CEO, Francisco Leon, present at the 20th International Celiac Disease Symposium, where he will provide an update on pharmaceutical research and development in #celiacdisease. He will also share more about our pioneering approach to preventing and treating celiac and other immune-related diseases by focusing on the thymus, the body’s master regulator of immune tolerance. #ICDS2024 #biotech
-